Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib and Abiraterone in mCRPC
NCT01553188Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2012
- Primary completion
- Apr 2017
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trebananib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Feb 2012; status: completed.
02
Drugs
trebananib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01553188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553188.